New Data Revealed at ASCO 2024: Lisaftoclax and Azacitidine Combo in AML

Tuesday, 4 June 2024, 02:04

The latest findings presented at ASCO 2024 showcase the efficacy and safety of combining Bcl-2 inhibitor Lisaftoclax with Azacitidine in patients with acute myeloid leukemia (AML). The updated data demonstrates promising results, indicating a potential new treatment avenue for AML patients with manageable safety profiles.

https://store.livarava.com/b98926ef-2230-11ef-a3fb-9d5fa15a64d8.jpg — New Data Revealed at ASCO 2024: Lisaftoclax and Azacitidine Combo in AML

ASCO 2024 Update on Lisaftoclax and Azacitidine in AML Patients

Live from ASCO 2024: Updated data on the combination of Bcl-2 inhibitor Lisaftoclax and Azacitidine in patients with acute myeloid leukemia (AML) shows promising efficacy and manageable safety. This treatment option presents a potential advancement in the management of AML.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.